Vise Technologies Inc. Makes New $1.80 Million Investment in Zoetis Inc. $ZTS

Vise Technologies Inc. bought a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,555 shares of the company’s stock, valued at approximately $1,802,000.

Several other institutional investors have also recently modified their holdings of the company. Allworth Financial LP lifted its stake in Zoetis by 8.7% during the 2nd quarter. Allworth Financial LP now owns 47,179 shares of the company’s stock valued at $7,358,000 after acquiring an additional 3,789 shares during the period. Compass Capital Management Inc. purchased a new position in Zoetis in the 2nd quarter valued at about $9,370,000. ProShare Advisors LLC boosted its stake in shares of Zoetis by 6.6% in the second quarter. ProShare Advisors LLC now owns 116,738 shares of the company’s stock worth $18,205,000 after acquiring an additional 7,211 shares during the last quarter. PFG Advisors grew its holdings in shares of Zoetis by 28.8% during the second quarter. PFG Advisors now owns 12,400 shares of the company’s stock worth $1,934,000 after buying an additional 2,773 shares in the last quarter. Finally, SFE Investment Counsel raised its holdings in Zoetis by 6.4% in the 2nd quarter. SFE Investment Counsel now owns 34,012 shares of the company’s stock valued at $5,304,000 after acquiring an additional 2,037 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on ZTS. Stifel Nicolaus set a $140.00 price target on Zoetis in a report on Tuesday, November 4th. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Morgan Stanley decreased their price target on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Finally, Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Six equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $180.00.

Zoetis Trading Up 0.3%

Shares of Zoetis stock opened at $120.09 on Wednesday. The company has a market capitalization of $52.92 billion, a P/E ratio of 20.67, a PEG ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a 1 year low of $117.26 and a 1 year high of $181.85. The company’s fifty day moving average is $142.82 and its two-hundred day moving average is $152.16. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period last year, the business posted $1.58 EPS. The company’s revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.